NO20076191L - Magnesiumsalter av HMG-COA reduktaseinhibitorer - Google Patents
Magnesiumsalter av HMG-COA reduktaseinhibitorerInfo
- Publication number
- NO20076191L NO20076191L NO20076191A NO20076191A NO20076191L NO 20076191 L NO20076191 L NO 20076191L NO 20076191 A NO20076191 A NO 20076191A NO 20076191 A NO20076191 A NO 20076191A NO 20076191 L NO20076191 L NO 20076191L
- Authority
- NO
- Norway
- Prior art keywords
- hmg
- coa reductase
- magnesium salts
- reductase inhibitors
- compositions
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
- 159000000003 magnesium salts Chemical class 0.000 title abstract 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1108DE2005 | 2005-05-03 | ||
| PCT/IB2006/051396 WO2006117761A2 (en) | 2005-05-03 | 2006-05-03 | Magnesium salts of hmg-coa reductase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076191L true NO20076191L (no) | 2008-01-30 |
Family
ID=37308379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076191A NO20076191L (no) | 2005-05-03 | 2007-11-30 | Magnesiumsalter av HMG-COA reduktaseinhibitorer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100222405A1 (de) |
| EP (2) | EP2172452A1 (de) |
| AT (1) | ATE496025T1 (de) |
| DE (1) | DE602006019710D1 (de) |
| DK (1) | DK1879862T3 (de) |
| ES (1) | ES2304911T3 (de) |
| NO (1) | NO20076191L (de) |
| PT (1) | PT1879862E (de) |
| WO (1) | WO2006117761A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2304335T3 (es) | 2005-11-21 | 2010-05-19 | Warner-Lambert Company Llc | Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio. |
| EP1963263A4 (de) * | 2005-11-29 | 2009-09-02 | Biocon Ltd | Polymorphe von [r-(r*,r*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure-magnesiumsalz (2:1) |
| WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
| SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
| IS8587A (is) * | 2006-12-27 | 2008-06-28 | Actavis Group Hf. | Atorvastatin lyfjasamsetning |
| WO2009063476A1 (en) * | 2007-11-16 | 2009-05-22 | Biocon Limited | A crystalline form of atorvastatin hemi magnesium salt and a process thereof |
| EP2130819A3 (de) | 2008-04-10 | 2009-12-23 | Ranbaxy Laboratories Limited | Kristalline Formen von Atorvastatin-Magnesium |
| WO2009157005A1 (en) * | 2008-06-26 | 2009-12-30 | Biocon Limited | Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| CA2413702A1 (en) * | 2000-06-28 | 2002-01-03 | Teva Pharmaceuticals Industries Ltd. | Carvedilol |
| AR038839A1 (es) * | 2002-02-14 | 2005-01-26 | Ranbaxy Lab Ltd | Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos. metodo para su elaboracion |
| WO2006054308A2 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| WO2006070248A1 (en) * | 2004-12-28 | 2006-07-06 | Ranbaxy Laboratories Limited | Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine |
| KR20070104447A (ko) * | 2005-02-10 | 2007-10-25 | 라이프사이클 파마 에이/에스 | 페노피브레이트 및 HMG-CoA 리덕타제 억제제의 고정용량 배합물을 포함하는 안정한 약학 조성물 |
| ES2304335T3 (es) * | 2005-11-21 | 2010-05-19 | Warner-Lambert Company Llc | Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio. |
| EP1963263A4 (de) * | 2005-11-29 | 2009-09-02 | Biocon Ltd | Polymorphe von [r-(r*,r*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure-magnesiumsalz (2:1) |
| WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
| SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
| US20090082421A1 (en) * | 2006-05-11 | 2009-03-26 | Biocon Limited | Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof |
| EP2130819A3 (de) * | 2008-04-10 | 2009-12-23 | Ranbaxy Laboratories Limited | Kristalline Formen von Atorvastatin-Magnesium |
-
2006
- 2006-05-03 ES ES06765662T patent/ES2304911T3/es not_active Expired - Lifetime
- 2006-05-03 US US11/913,582 patent/US20100222405A1/en not_active Abandoned
- 2006-05-03 DE DE602006019710T patent/DE602006019710D1/de not_active Expired - Lifetime
- 2006-05-03 DK DK06765662.9T patent/DK1879862T3/da active
- 2006-05-03 PT PT06765662T patent/PT1879862E/pt unknown
- 2006-05-03 AT AT06765662T patent/ATE496025T1/de active
- 2006-05-03 WO PCT/IB2006/051396 patent/WO2006117761A2/en not_active Ceased
- 2006-05-03 EP EP08161846A patent/EP2172452A1/de not_active Withdrawn
- 2006-05-03 EP EP06765662A patent/EP1879862B1/de not_active Revoked
-
2007
- 2007-11-30 NO NO20076191A patent/NO20076191L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100222405A1 (en) | 2010-09-02 |
| EP1879862B1 (de) | 2011-01-19 |
| ATE496025T1 (de) | 2011-02-15 |
| ES2304911T1 (es) | 2008-11-01 |
| PT1879862E (pt) | 2011-04-19 |
| WO2006117761A2 (en) | 2006-11-09 |
| DK1879862T3 (da) | 2011-05-16 |
| DE602006019710D1 (de) | 2011-03-03 |
| ES2304911T3 (es) | 2011-05-30 |
| EP1879862A2 (de) | 2008-01-23 |
| WO2006117761A3 (en) | 2007-03-29 |
| EP2172452A1 (de) | 2010-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| NO20080141L (no) | Indanderivater som modulatorer av ionekanaler | |
| EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
| NO20076447L (no) | Bicykliske derivater som modulatorer av ionekanaler | |
| NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
| NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
| NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
| NO20083220L (no) | Heterocykliske derivater som modulatorer for ionekanaler | |
| ATE497961T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
| EA200702048A1 (ru) | Фармакокинетически улучшенные соединения | |
| ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
| NO20082508L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| WO2008033562A3 (en) | Kinase inhibitor compounds | |
| NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
| NO20064852L (no) | Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser | |
| SG151327A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
| NO20074446L (no) | DR5-antistoffer og anvendelser derav | |
| DE602006021776D1 (de) | Als kinaseinhibitoren geeignete aminopyrimidine | |
| DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
| MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
| NO20092130L (no) | Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase | |
| TW200616953A (en) | Indole, indazole or indoline derivatives | |
| NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
| EA200801008A1 (ru) | Гипохолестеринемические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |